The cellular neurobiology of depression
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Major depressive disorders, long considered to be of neurochemical origin, have recently been associated with impairments in signaling pathways that regulate neuroplasticity and cell survival. Agents designed to directly target molecules in these pathways may hold promise as new therapeutics for depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antidepressant therapies may compensate for this dysfunction by modulating the pathological limbic activity that putatively mediates depressive symptoms (Drevets et al, 2002a), or by enhancing the expression of neurotrophic factors that protect medial network function from the effects of repeated stress (Manji et al, 2001).”
From Neurocircuitry of Mood Disorders (2010) · cites this paper as Manji et al, 2001
In the citing paper
“Somatic antidepressant therapies may compensate for this dysfunction by modulating the pathological limbic activity which putatively mediates depressive symptoms (Drevets et al. 2002a) and the expression of neurotrophic/neuroprotective factors that preserve the function of the MPFC (Manji et al. 2001).”
From Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression (2008) · cites this paper as Manji et al. 2001
In the citing paper
“Depression is often associated with elevated HPA axis activity and increased levels of glucocorticoids, as well as disruption of negative feedback mechanisms21–23.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [22]
Citations
Cites
Neurogenesis in the adult human hippocampus
Eriksson, P. S., Perfilieva, E., Björk-Eriksson, T., Alborn, A.-M., Nordborg, C., Peterson, D. A., & Gage, F. H. (1998) · Nature Medicine · doi:10.1038/3305 · Cited by 6,369 · cited 1×
“However, the demonstration that neurogenesis occurs in the adult human brain into senescenc”
BackgroundThe Bcl-2 Protein Family: Arbiters of Cell Survival
Adams, J. M., & Cory, S. (1998) · Science · doi:10.1126/science.281.5381.1322 · Cited by 5,332 · cited 1×
“Modest changes in this signaling cascade or in the levels of the Bcl-2 family of proteins (potentially due to genetic, illness or insult-related factors) could therefore profoundly affect cellular viabilit”
BackgroundGlobal mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492 · cited 1×
“It is thus not altogether surprising that the Global Burden of Disease Study has identified MDDs among the leading causes of disability worldwide, and as illnesses likely to represent an increasingly greater health, societal and economic problem in the coming year”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“Current research is examining the potential efficacy of antagonists of corticotropin-releasing factor (CRF), antiglucocorticoids and direct and indirect glutamate antagonist”
BackgroundSelf-citationChronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111 · cited 1×
“These studies demonstrate that chronic administration of different classes of antidepressants increases the proliferation and survival of new neuron”
BackgroundPsychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301 · cited 1×
“Moreover, lithium also inhibits the activity of glycogen synthase kinase 3β (GSK-3β”
BackgroundThe Corticosteroid Receptor Hypothesis of Depression
Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129 · cited 1×
“have demonstrated that an important pathway involved in cell survival and plasticity, the cAMP–CREB cascade, is up-regulated by antidepressant treatmen”
BackgroundTHE EFFECTS OF STRESSFUL LIFE EVENTS ON DEPRESSION
Kessler, R. C. (1997) · Annual Review of Psychology · doi:10.1146/annurev.psych.48.1.191 · Cited by 2,111 · cited 1×
“Thus, although MDDs undoubtedly have a strong genetic basis, severe stressors have been associated with a substantial increase in risk for the onset of MDDs in susceptible individuals ( Table 3”
Background
Research works printed but not linked: 4
- Garlow, S.J., Musselman, D.L. & Nemeroff C.B. The Neurochemistry of Mood Disorders clinical studies. in Neurobiology of Mental Illness. (eds. Charney, D.S., Nester, E.J. & Bunney, B.S.) 348–364 (Oxford Press, New York, 1999).
- Drevets, W.C., Gadde, K. & Krishnan, R. Neuroimaging studies of depression. in Neurobiology of Mental Illness. (eds. Charney, D.S., Nester, E.J. & Bunney, B.S.) 394–418 (Oxford Press, New York, 1999).
- LeDoux, J.E. Emotion. in Handbook of Physiology—The Nervous System, Vol. V. (eds. Mills, J., Mountcastle, V.B., Plum, F. & Geiger, S.R.) 373–417 (Williams & Wilkins, Baltimore, 1987).
- Manji, H.K. et al. Regulation of signal transduction pathways by mood stabilizing agents: Implications for the pathophysiology and treatment of bipolar affective disorder. in Bipolar Medications: Mechanisms of Action. (eds. Manji, H.K., Bowden, C.L. & Belmaker, R.H.) 129–177 (American Psychiatric Press, Washington, DC, 2000).
Cited by
Items 401–500 of 1,000
A population‐based association study of candidate genes for depression and sleep disturbance
Utge, S., Soronen, P., Partonen, T., Loukola, A., Kronholm, E., Pirkola, S., Nyman, E., Porkka‐Heiskanen, T., & Paunio, T. (2010) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31002 · Cited by 62
“Multiple lines of evidence have also implicated for the role of neuroplasticity in depression, and adaptive changes in neuroplasticity are likely to be involved in therapeutic effect of antidepressant medication [Manji et al., 2001; Castren, 2005].”
BackgroundShayganfard, M. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00491-3 · Cited by 66
Morales‐Medina, J. C., Juárez, I., Venancio-García, E., Cabrera, S. N., Ménard, C., Yu, W., Flores, G., Mechawar, N., & Quirion, R. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.01.037 · Cited by 65
“233 Major depression has been associated with disrupted neuronal plasticity (Manji et al., 2001) and deregulated hippocampal neurogenesis (Boldrini et al., 2009).”
Deep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D. A., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.1.foc143 · Cited by 62
New insights on the antidepressant discontinuation syndrome
Harvey, B. H., & Slabbert, F. N. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2429 · Cited by 58
“…time-dependent neuroplastic events, not unlike that observed when an antidepressant is started up until the onset of therapeutic effects some weeks later (see Manji et al., 2001; Popoli et al., 2002; Krishnan and Nestler, 2008, for review), and which will be touched on later in this review.”
BackgroundDjordjevic, A. D., Djordjevic, J., Elaković, I., Adžić, M., Matić, G. M., & Radojcic, M. B. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.10.006 · Cited by 63
“Both antidepressants and stress can affect a number of factors involved in cell survival pathways controling Bcl-2 expression (Manji et al., 2001), among which is the nuclear factor kappa B (NFκB) (Kucharczak et al.”
BackgroundJangra, A., Kwatra, M., Singh, T., Pant, R., Kushwah, P., Sharma, Y., Saroha, B., Datusalia, A. K., & Bezbaruah, B. K. (2016) · Inflammation · doi:10.1007/s10753-016-0332-4 · Cited by 69
Apoptosis Detected in the Amygdala Following Myocardial Infarction in the Rat
Wann, B. P., Boucher, M., Kaloustian, S., Nim, S., Godbout, R., & Rousseau, G. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.018 · Cited by 60
A New Outlook on Mental Illnesses: Glial Involvement Beyond the Glue
Elsayed, M., & Magistretti, P. J. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00468 · Cited by 59
“The disruption of this circuitry is further substantiated by anatomical studies indicating cellular and myelination changes in many of these brain regions (Zhu et al., 1999; Manji et al., 2001).”
BackgroundResultŻurawek, D., & Turecki, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111312 · Cited by 72
“Depression is associated with abnormalities in the maintenance of homeostasis and normal neuronal activity in many regions of the brain [1].”
BackgroundMicroglial activation contributes to depressive-like behavior in dopamine D3 receptor knockout mice
Wang, J., Lai, S., Li, G., Zhou, T., Wang, B., Cao, F., Chen, T., Zhang, X., & Chen, Y. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.10.016 · Cited by 64
Brain creatine kinase activity in an animal model of mania
STRECK, E. L., Amboni, G., Scaini, G., Di‐Pietro, P. B., Rezin, G. T., Valvassori, S. S., da Luz, G., Kapczinski, F. P., & Quevedo, J. (2008) · Life Sciences · doi:10.1016/j.lfs.2007.11.026 · Cited by 60
Altered glucocorticoid receptor signaling cascade in lymphocytes of bipolar disorder patients
Spiliotaki, M., Salpeas, V., Malitas, P., Alevizos, V., & Moutsatsou, P. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2006.02.006 · Cited by 58
Colaço, C. S., Alves, S. S., Nolli, L. M., Pinheiro, W. O., de Oliveira, D. G. R., Santos, B. W. L., Pic-Taylor, A., Mortari, M. R., & Caldas, E. D. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00547-w · Cited by 58
Peritore, A. F., Crupi, R., Scuto, M. C., Gugliandolo, E., Siracusa, R., Impellizzeri, D., Cordaro, M., D’Amico, R., Fusco, R., Paola, R. D., et al. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200107094732 · Cited by 59
Genome Wide Gene Expression Studies in Mood Disorders
Sequeira, A., & Turecki, G. (2006) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2006.10.444 · Cited by 58
“More recent work has suggested the possible role of neuropeptides (Garlow et al., 1999; Nemeroff, 2002), as well as downstream alterations, particularly in signaling pathways, as etiologically relevant to mood disorders (Manji et al., 2001).”
Vinet, J., Carra, S., Blom, J. M. C., Brunello, N., Barden, N., & Tascedda, F. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.07.035 · Cited by 72
Howell, B. R., & Sanchez, M. M. (2011) · Development and Psychopathology · doi:10.1017/s0954579411000460 · Cited by 57
Brainstem Aminergic Nuclei and Late-Life Depressive Symptoms
Wilson, R. S., Nag, S., Boyle, P. A., Hizel, L. P., Yu, L., Buchman, A. S., Shah, R. C., Schneider, J. A., Arnold, S. E., & Bennett, D. A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2224 · Cited by 60
Ramirez-Mahaluf, J. P., Roxin, A., Mayberg, H. S., & Compte, A. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhv249 · Cited by 58
“Converging clinical, biochemical, neuroimaging, and postmortem evidence demonstrates cortical, subcortical, and limbic involvement in the pathophysiology of MDD (Mayberg 1997; Manji et al. 2001; Vaidya andDuman 2001; Nemeroff 2002; Nestler et al. 2002).”
BackgroundTherapeutic potential of agmatine for CNS disorders
Neis, V. B., da Rosa, P. B., Olescowicz, G., & Rodrigues, A. L. S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.05.006 · Cited by 65
“…patients do not experience remission and 30%e40% do not show a significant response), the long time period (4e5 weeks) necessary for these drugs to afford remission of the depressive symptoms as well as the side effects associated with the treatment (Berton and Nestler, 2006; Manji et al., 2001).”
Masrour, F. F., Peeri, M., Azarbayjani, M. A., & Hosseini, M. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2519-6 · Cited by 63
Wong, M.-L., O'Kirwan, F., HANNESTAD, J., Irizarry, K. J. L., Elashoff, D. A., & Licinio, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001470 · Cited by 62
Komlósi, G., Molnár, G., Rózsa, M., Oláh, S., Barzó, P., & Tamás, G. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2618-12.2012 · Cited by 57
“…problems in neuronal communication could be more important in depression compared with chemical imbalance and antidepressants might improve information processing in impaired neuronal networks by causing functional and structural changes (Manji et al., 2001; Nestler et al., 2002; Castrén, 2005).”
BackgroundInfluentialWang, Z.-F., Fessler, E. B., & Chuang, D.-M. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.140 · Cited by 57
Larger amygdala volume in first-degree relatives of patients with major depression
Romanczuk-Seiferth, N., Pöhland, L., Mohnke, S., Garbusow, M., Erk, S., Haddad, L., Grimm, O., Tost, H., Meyer-Lindenberg, A., Walter, H., et al. (2014) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.05.015 · Cited by 56
Intravenous Ketamine for Treatment-Resistant Major Depressive Disorder
Covvey, J. R., Crawford, A. N., & Lowe, D. K. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q371 · Cited by 58
Duval, F., Lebowitz, B. D., & Macher, J. P. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.2/fduval · Cited by 75
Kesby, J. P., Markou, A., & Semenova, S. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.06.011 · Cited by 57
“However, the response to antidepressant treatment in depression is complicated and aspects of plasticity-mediated brain changes may be more relevant than discrete actions on serotonergic function (Manji et al., 2001).”
BackgroundBreuer, M. E., Chan, J. S. W., Oosting, R. S., Groenink, L., Korte, S. M., Campbell, U. C., Schreiber, R., Hanania, T., Snoeren, E. M. S., Waldinger, M. D., et al. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.07.011 · Cited by 60
“The World Health Organization says it will be the second largest global burden of disease (DALYs) by the year 2020, illustrating the severity and impact of the disorder (Manji et al., 2001; Nestler et al., 2002).”
BackgroundMultimodal Investigations of Reward Circuitry and Anhedonia in Adolescent Depression
Ely, B. A., Nguyen, T. N. B., Tobe, R. H., Walker, A., & Gabbay, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.678709 · Cited by 60
Haj‐Mirzaian, A., Kordjazy, N., Haj‐Mirzaian, A., Ostadhadi, S., Ghasemi, M., Amiri, S., Faizi, M., & Dehpour, A. R. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4004-0 · Cited by 58
“Recently, discovery of the rapid antidepressant effect of NMDA receptors antagonists has linked the glutamatergic system to the pathophysiology of depression (Manji et al. 2001) and the mechanism of action of some antidepressants (Berman et al.”
Virus-induced neurobehavioral disorders: mechanisms and implications
Tomonaga, K. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.12.001 · Cited by 51
“The reduction of 5-HT through tryptophan depletion induces depressive effects [39, 40] .”
BackgroundMolteni, R., Chourbaji, S., Brandwein, C., Racagni, G., Gass, P., & Riva, M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108099815 · Cited by 57
Carboni, L., Vighini, M., Piubelli, C., Castelletti, L., Milli, A., & Domenici, E. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.01.007 · Cited by 61
“Recent studies on the pathophysiology of mood disorders and the mechanism of action of antidepressive agents suggested the involvement of alterations in neural plasticity (Manji et al., 2001; Duman, 2002; D’Sa and Duman, 2002).”
BackgroundKozlovsky, N., Matar, M. A., Kaplan, Z., Kotler, M., Zohar, J., & Cohen, H. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.04.009 · Cited by 58
“It is well known that antidepressant drugs reinforce synaptic strength in mood-related brain regions in a manner akin to that achieved in experimental models of synaptic plasticity (Duman, 2002; Manji et al., 2001).”
ResultRogers, J., Martin, L. J., Comuzzie, A. G., Mann, J. J., Manuck, S. B., Leland, M. M., & Kaplan, J. R. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.12.017 · Cited by 56
Depression, the Perimenopause, and Estrogen Therapy
Schmidt, P. J. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1347.003 · Cited by 61
DU, J., GRAY, N. A., FALKE, C., YUAN, P., SZABO, S., & MANJI, H. K. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.031 · Cited by 57
Self-citationSalicylate-induced tinnitus: molecular mechanisms and modulation by anxiety
Puel, J., & Guitton, M. J. (2007) · Progress in brain research · doi:10.1016/s0079-6123(07)66012-9 · Cited by 55
Tuberoinfundibular peptide of 39 residues produces anxiolytic and antidepressant actions
LaBuda, C. J., Dobolyi, Á., & Usdin, T. B. (2004) · Neuroreport · doi:10.1097/00001756-200404090-00030 · Cited by 58
“In addition, recent neuroimaging studies demonstrated abnormalities (increased blood flow, glucose metabolism) in the infralimbic cortex and the paraventricular thalamic nucleus of depressed patients [6,8].”
BackgroundMugge, L., Mansour, T. R., Crippen, M., Alam, Y., & Schroeder, J. L. (2018) · Neurosurgical Review · doi:10.1007/s10143-018-1017-2 · Cited by 65
Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders
Brunello, N., & Tascedda, F. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003419 · Cited by 58
HCN Channel Targets for Novel Antidepressant Treatment
Ku, S. M., & Han, M.-H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0538-7 · Cited by 54
Sun, H., Guan, L., Zhu, Z., & Li, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081775 · Cited by 61
“important role in the pathophysiology of depression [7,8].”
BackgroundŻurawek, D., Faron-Górecka, A., Kuśmider, M., Kolasa, M., Gruca, P., Papp, M., & Dziedzicka-Wasylewska, M. (2013) · Psychopharmacology · doi:10.1007/s00213-013-2990-3 · Cited by 54
“The behavioural response to stress depends on various factors and systems and their mutual relationships at different levels (Manji et al. 2001).”
BackgroundAdvances in the treatment of anxiety: Targeting glutamate
Simon, A. B., & Gorman, J. M. (2006) · NeuroRx · doi:10.1016/j.nurx.2005.12.005 · Cited by 70
“See reviews by Manji et al.17 and Duman and Carlson et al.115,116 This shrinkage appears to disrupt the functionality of the neurons and their signaling, but it may in fact be compensatory or adaptive.117 In postsynaptic neurons in the CNS, NMDA and AMPA receptors are actively shuttled between the membrane and cytopla…”
Ohashi, S., Matsumoto, M., Otani, H., Mori, K., Togashi, H., Ueno, K.-I., Kaku, A., & Yoshioka, M. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02973-6 · Cited by 54
Kuipers, S. D., Trentani, A., Westenbroek, C., Bramham, C. R., Korf, J., Kema, I. P., Horst, G. J. T., & den Boer, J. A. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.10.006 · Cited by 60
Poor performance on cognitive tasks in depression: Doing too much or not enough?
Jones, N. P., Siegle, G. J., Muelly, E. R., Haggerty, A., & Ghinassi, F. (2010) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/cabn.10.1.129 · Cited by 55
“In light of our findings, our posited resource allocation model of cognitive deficits in depression would benefit from being expanded to incorporate individual differences in depression, such as exposure to stress and motivational impairment (Carragher, Adamson, Bunting, & McCann, 2009; Chen, Eaton, Gallo, & Nestadt,…”
BackgroundPhosphorylation of MeCP2 at Ser421 Contributes to Chronic Antidepressant Action
Hutchinson, A. N., Deng, J. V., Cohen, S., & West, A. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2156-12.2012 · Cited by 53
“Activation of monoamine receptors is essential to the mechanism by which tricyclic antidepressants and selective-serotonin reuptake inhibitors (SSRIs) alleviate symptoms of depression (Manji et al., 2001).”
BackgroundClerici, L., Bottari, D., & Bottari, B. (2025) · Current Nutrition Reports · doi:10.1007/s13668-025-00619-2 · Cited by 59
Piubelli, C., Carboni, L., Becchi, S., Mathé, A. A., & Domenici, E. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.12.043 · Cited by 56
“Several hypotheses about the mechanism of disease have been proposed based on studies on patients and animal models, but none of them was conclusively proved (Manji et al., 2001; Nestler et al., 2002; Belmaker and Agam, 2008; Pariante and Lightman, 2008).”
BackgroundMolecular Mechanisms Underlying the Anti-depressant Effects of Resveratrol: a Review
de Oliveira, M. R., Chenet, A. L., Duarte, A. R., Scaini, G., & Quevedo, J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0680-6 · Cited by 57
“Studies on the pathophysiology of major depressive disorder reveal that there is a reduction in monoamine neurotransmitter systems including serotonin, dopamine, and noradrenaline [15], beyond neuronal cell loss and damage to signaling pathways that control cell neuroplasticity and survival [15, 16].”
BackgroundHalloway, S., Arfanakis, K., Wilbur, J., Schoeny, M. E., & Pressler, S. J. (2018) · The Journals of Gerontology Series B · doi:10.1093/geronb/gby010 · Cited by 56
Acupuncture – Self-Appraisal and the Reward System
Lundeberg, T., Lund, I., & Näslund, J. (2007) · Acupuncture in Medicine · doi:10.1136/aim.25.3.87 · Cited by 56
“While the hippocampus and frontal cortex are involved in aspects of chronic pain and mood disorders, these regions do not account for all symptoms.(86-101) In recent years a role for other parts of the brain including the brain’s reward regions have been demonstrated.”
Gao, H.-Q., Zhu, H., Zhang, Y.-Q., & Wang, L. (2008) · Clinical and investigative medicine · doi:10.25011/cim.v31i6.4921 · Cited by 56
Wang, Z., Zhang, Y., Liu, Y., Zhao, N., Zhang, Y., Li, Y., An, L., Li, J., Wang, X., Qin, J., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02225.x · Cited by 59
“PDE4-mediated cAMP signalling is essential for the regulation of neuronal plasticity (Sakamoto et al., 2011; Antoni, 2012), which is associated with processes of emotion (Manji et al., 2001) and memory (Dumitriu et al., 2010).”
BackgroundInfluentialPineda, E. A., Hensler, J. G., Sankar, R., Shin, D., Burke, T. F., & Mazarati, A. M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.18 · Cited by 50
“…et al., 2007; Plotsky et al., 1998; Yu et al., 2008) and the deficit of brain serotonergic system (Kondziella et al., 2007; Lanfumey et al., 2008; Manji et al., 2001; Mann et al., 1989) are recognized both as hallmarks and putative mechanistic factors of major depression; therefore our…”
Patel, S. S., Mehta, V., Changotra, H., & Malairaman, U. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.11.010 · Cited by 51
Wang, Z.-Z., Yang, W.-X., Zhang, Y., Zhao, N., Zhang, Y.-Z., Liu, Y.-Q., Xu, Y., Wilson, S. P., O'Donnell, J. M., Zhang, H.-T., et al. (2015) · Scientific Reports · doi:10.1038/srep11332 · Cited by 51
“8 mA, 5-s duration, 60-s inter-shock interval); (6) white noise (110 dB); (7) tail pinch (1 cm apart from the end of the tail); (8) damp sawdust (200 ml water absorbed in sawdust bedding); (9) sawdust-free cage; (10) sawdust-free cage with 200 ml water (21 °C); (11) continuous cage shaking (high speed horizontal shaki…”
BackgroundNanosensors for the Chemical Imaging of Acetylcholine Using Magnetic Resonance Imaging
Luo, Y., Kim, E. H., Flask, C. A., & Clark, H. A. (2018) · ACS Nano · doi:10.1021/acsnano.8b01640 · Cited by 51
Barbiero, V. S., Giambelli, R., Musazzi, L., Tiraboschi, E., Tardito, D., Pérez, J., Drago, F., Racagni, G., & Popoli, M. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301378 · Cited by 53
“…selective modulation of intracellular signaling cascades, and in turn modifications in gene expression, dendritic remodeling, synaptic plasticity, and neurogenesis (Manji et al, 2001; Coyle and Duman, 2003; Zarate et al, 2003; Wong and Licinio, 2004; Spedding et al, 2005; Tardito et al, 2006).”
BackgroundDiagnosis and Treatment of Major Depressive Disorder
Soleimani, L., Lapidus, K. A. B., & Iosifescu, D. V. (2010) · Neurologic Clinics · doi:10.1016/j.ncl.2010.10.010 · Cited by 57
Siegel, J. S., Palanca, B. J. A., Ances, B. M., Kharasch, E. D., Schweiger, J. A., Yingling, M. D., Snyder, A. Z., Nicol, G. E., Lenze, E. J., & Farber, N. B. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05762-6 · Cited by 50
“The delayed therapeutic benefit of monoaminergic antidepressants has been linked to a slow increase in neurogenesis (particularly in the hippocampus) and transcriptional alterations that reconfigure neuronal circuits (Manji et al. 2001; Santarelli et al. 2003; Adachi et al. 2008).”
BackgroundBDNF Val66Met genotype and 6-month remission rates in late-life depression
Taylor, W. D., McQuoid, D. R., Ashley-Koch, A., MacFall, J. R., Bridgers, J., Krishnan, R. R., & Steffens, D. C. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.12 · Cited by 50
Effect of desipramine and fluoxetine on energy metabolism of cerebral mitochondria
Villa, R. F., Ferrari, F., Gorini, A., Brunello, N., & Tascedda, F. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.05.051 · Cited by 49
Xue, T., Yan, M., Wang, L., Zhou, Y., Wang, Z., Xia, T., Liu, X., Pan, R., & Chang, Q. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041460 · Cited by 51
“In the clinical neuroscience community, considerable evidences have been demonstrated that dysfunctional neuroplasticity might underlie the pathophysiology of depression, and antidepressants exerted a significant influence on neuroplasticity [16].”
BackgroundRantamäki, T., Knuuttila, J. E. A., Hokkanen, M., & Ċastrén, E. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.10.001 · Cited by 63
“Recent evidence suggests that insufficient neurotrophin function is a key factor in the etiology of mood disorders: neuropathological and neuroimaging studies of bipolar and depressive patients have demonstrated that these disorders are frequently associated with atrophic changes in neuronal and/ or glial cells, parti…”
BackgroundGressèns, P., Schwendimann, L., Husson, I., Sárközy, G., Mocaër, E., Vamecq, J., & Spedding, M. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.04.016 · Cited by 51
Changes in rat hippocampal CA1 synapses following imipramine treatment
Chen, F., Madsen, T. M., Wegener, G., & Nyengaard, J. R. (2008) · Hippocampus · doi:10.1002/hipo.20423 · Cited by 49
“Indeed, neurotrophic effects of antidepressants could help to restore the functional network by inducing neurogensis, synaptogenesis, and remodelling of synapses (Manji et al., 2001; Duman, 2002; Warner-Schmidt and Duman, 2006).”
BackgroundMismatch negativity in treatment-resistant depression and borderline personality disorder
He, W., Chai, H., Zheng, L., Yu, W., Chen, W., Li, J., Chen, W., & Wang, W. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.12.021 · Cited by 48
Effect of fluoride exposure on anxiety- and depression-like behavior in mouse
Li, X., Zhang, J., Niu, R., Manthari, R. K., Yang, K., & Wang, J. (2018) · Chemosphere · doi:10.1016/j.chemosphere.2018.10.070 · Cited by 50
Review: Magnetic Resonance Spectroscopy Studies of Pediatric Major Depressive Disorder
Kondo, D. G., Hellem, T. L., Sung, Y.-H., Kim, N., Jeong, E.-K., DelMastro, K. K., Shi, X., & Renshaw, P. F. (2011) · Depression Research and Treatment · doi:10.1155/2011/650450 · Cited by 48
Wu, F., Li, H., Zhao, L., Li, X., You, J., Jiang, Q., Li, S., Jin, L., & Xu, Y. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.05.026 · Cited by 51
Moussaieff, A., Gross, M., Nesher, E., Tikhonov, T., Yadid, G., & Pinhasov, A. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112458729 · Cited by 49
“In contrast to IA, most clinically available antidepressants’ effects are mediated by alterations in monoamine and/or catecholamine signaling, which are achieved by mechanisms that are still poorly understood (Manji et al., 2001; Uppal et al., 2010).”
BackgroundMechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders
Ghasemi, M., Phillips, C., Fahimi, A., McNerney, M. W., & Salehi, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.002 · Cited by 58
“While this strategy has demonstrated some utility in alleviating symptoms, their slow pace of action (3-5 weeks), extensive side-effects, and poor response in a significant proportion of persons treated (65 to 75%) remain significant limitations (Manji et al., 2001; Oswald et al., 1972; Paul and Skolnick, 2003; Trived…”
InfluentialChallenge and Prospect of Traditional Chinese Medicine in Depression Treatment
Zhang, Y., & Cheng, Y. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00190 · Cited by 55
D'Sa, C. M., Eisch, A. J., Bolger, G. B., & Duman, R. S. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04321.x · Cited by 49
“Brain imaging studies have demonstrated impairments in cerebral blood flow and decreased cortical and hippocampal volume in depressed patients, effects that could contribute to the cognitive dysfunction observed in mood disorders (reviewed by Manji et al., 2001).”
BackgroundTroelsen, K. B., Nielsen, E. Ø., & Mirza, N. R. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0032-5 · Cited by 49
“However, the mouse zero maze represents a model able to discriminate between acute and chronic antidepressant treatment, and as such may be useful for correlating behavioural changes with time-dependent changes in various biomarkers currently thought to be relevant to the delayed onset of efficacy of antidepressants i…”
BackgroundSchiffer, H. H. (2002) · Molecular Neurobiology · doi:10.1385/mn:25:2:191 · Cited by 56
“A great deal of attention has focused on the dysfunction of the monoamine receptor systems, particularly those for the neurotransmitters norepinephrine, serotonin, and dopamine, which have been consistently found to be altered in depressive disorders (2).”
BackgroundBernstein, H.-G., Meyer-Lotz, G., Dobrowolny, H., Bannier, J., Steiner, J., Walter, M., & Bogerts, B. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00273 · Cited by 47
“Initially, search for the possible cellular substrate of mood disorder pathology had focused on neurons (Rajkowska, 2000, 2002; Cotter et al., 2001a,b, 2002; Manji et al., 2001).”
BackgroundNeuronal localization of the 5-HT2 receptor family in the amygdaloid complex
Bombardi, C. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00068 · Cited by 53
“REVIEW ARTICLE published: 09 April 2014 doi: 10.3389/fphar.2014.00068 Neuronal localization of the 5-HT2 receptor family in the amygdaloid complex”
InfluentialBenton, C. S., Miller, B. H., Skwerer, S., Suzuki, O., Schultz, L. E., Cameron, M. D., Marron, J. S., Pletcher, M. T., & Wiltshire, T. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2574-z · Cited by 49
“Many analytes, including brain-derived neurotrophic factor (BDNF), serotonin transporter, and monoamines, have been linked with depressive symptoms and response to antidepressant therapy (Manji et al. 2001; Nestler et al. 2002; Thase 2007).”
BackgroundLin, Y., Westenbroek, C., Bakker, P., Termeer, J., Liu, A., Li, X., & Ter Horst, G. J. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhn035 · Cited by 49
“animals but also in depressed patients (McEwen 2000; Manji et al. 2001).”
BackgroundWang, H.-N., Ye, P., Tan, Q.-R., Chen, Y.-C., Zhang, R.-G., Qiao, Y.-T., Wang, H.-H., Liu, L., Kuang, F., Wang, B.-R., et al. (2010) · Physiological Research · doi:10.33549/physiolres.931756 · Cited by 50
Yan, A. L., Hu, Q., Mak, S., Lou, J.-S., Xu, S. L., Bi, C. W. C., Zhu, K. Y., Wang, H., Dong, T. T.-X., & Tsim, K. W. K. (2016) · Scientific Reports · doi:10.1038/srep30014 · Cited by 54
Hayasaka, S., Nakamura, M., Noda, Y., Izuno, T., Saeki, T., Iwanari, H., & Hirayasu, Y. (2017) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12547 · Cited by 47
Tagliari, B., Noschang, C. G., Ferreira, A. G. K., Ferrari, O. A., Feksa, L. R., Wannmacher, C. M. D., Dalmaz, C., & Wyse, Â. T. D. S. (2010) · Metabolic Brain Disease · doi:10.1007/s11011-010-9194-x · Cited by 50
“On the other hand, it has been showed that the blood flow is reduced in some regions of prefrontal cortex of depressed patients (Manji et al. 2001) what could cause a reduction of oxidative metabolism, as found in the present study.”
ResultGazal, M., Souza, L. D., Fucolo, B. A., Wiener, C. D., Silva, R. A., Pinheiro, R. T., Jansen, K., Ghislene, G., Oses, J. P., & Kaster, M. P. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.03.002 · Cited by 47
“Studies with antidepressants emphasize a bottomup chain of events, including monoaminergic reuptake inhibition associated with synaptic plasticity and neurotrophic effects (Manji et al., 2001).”
BackgroundYamauchi, J., Torii, T., Kusakawa, S., Sanbe, A., Nakamura, K., Takashima, S., Hamasaki, H., Kawaguchi, S., Miyamoto, Y., & Tanoue, A. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22460 · Cited by 52
“VPA is a known histone deacetylase (HADC) inhibitor (Manji et al., 2001; Coyle and Duman, 2003).”
BackgroundMethodInfluentialThe Antidepressant Effect ofGastrodia elataBl. on the Forced-Swimming Test in Rats
Chen, P., Hsieh, C., Su, K., Hou, Y., Chiang, H., Lin, I.-H., & Sheen, L. (2008) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x08005618 · Cited by 47
“Assessments of cerebrospinal fluid (CSF) chemistry, neuroendocrine responses to pharmacological challenge, and neuroreceptor and transporter binding have demonstrated the abnormalities in the serotonergic, noradrenergic, and dopaminergic systems in patients with major depressive disorders (Manji et al., 2001).”
BackgroundKozisek, M. E., Middlemas, D. S., & Bylund, D. B. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.08.001 · Cited by 54
Glutamate modulators as novel interventions for mood disorders
Mathew, S. J., Keegan, K., & Smith, L. (2005) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462005000300016 · Cited by 45
Bah, T. M., Benderdour, M., Kaloustian, S., Karam, R., Rousseau, G., & Godbout, R. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.07.039 · Cited by 53
Corrêa, C., Amboni, G., Assis, L. C., Martins, M. R., Kapczinski, F. P., STRECK, E. L., & Quevedo, J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.02.005 · Cited by 48
“Recent studies have demonstrated that changes in intracellular pathways that regulate neuronal transmission, plasticity and survival are associated with the pathophysiology of bipolar disorder (Coyle and Duman, 2003; Bezchlibnyk and Young, 2002; Manji et al., 2001).”
Background5HT1B receptor-mediated pre-synaptic depression of excitatory inputs to the rat lateral habenula
Hwang, E.-K., & Chung, J.-M. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.01.046 · Cited by 53
Simultaneous projections from prefrontal cortex to dopaminergic and serotonergic nuclei
Vázquez-Borsetti, P., Celada, P., Cortés, R., & Artigas, F. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000349 · Cited by 46
“Moreover, alterations of the PFC have been reported in severe psychiatric conditions such as depression and schizophrenia which are also associated with derangements of both monoaminergic systems (see for review Benes & Berretta, 2001 ; Drevets, 2001 ; Harrison, 1999; Lewis et al. 2005; Manji et al. 2001; Selemon & Go…”
BackgroundAP-1 controls the p11-dependent antidepressant response
Chottekalapanda, R. U., Kalik, S., Gresack, J. E., Ayala, A., Gao, M., Wang, W., Meller, S. J., Aly, A., Schaefer, A., & Greengard, P. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0767-8 · Cited by 49
Wu, Z., Xiao, L., Wang, H., & Wang, G. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107653 · Cited by 52
Metadata
- Authors
- Manji, H. K., Drevets, W. C., & Charney, D. S.
- Affiliations
- National Institutes of Health (US)
- National Institute of Mental Health (US)
- Corresponding author
- Manji, Husseini K.
- Venue
- Nature Medicine
- Published
- 2001-05
- Volume
- 7
- Issue
- 5
- Pages
- 541-547
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1509868652
- Cited by
- 1,182
- References
- 66
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 20 · 2023: 21 · 2022: 33 · 2021: 55 · 2020: 29 · 2019: 29 · 2018: 28 · 2017: 30 · 2016: 36 · 2015: 51 · 2014: 50 · 2013: 60 · 2012: 60
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- major depressive disorder, neurobiology of depression, neuroplasticity, cell survival, signaling pathways
- MeSH terms
- Antidepressive Agents, Cell Survival, Depressive Disorder, Glucocorticoids, Neuronal Plasticity, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.